Want to see SE:LARK full AI Analyst Report?
LARK Stock Chart & Stats
kr2.35
--
Market closed
kr2.35
--
Day’s Range― - ―
52-Week Rangekr1.75 - kr2.87
Previous CloseN/A
VolumeN/A
Average Volume (3M)41.41K
Market Cap
kr45.15M
Enterprise Value-kr14.34M
Total Cash (Recent Filing)kr5.84M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield89.69%
Share Statistics
EPS (TTM)-0.62
Shares Outstanding19,801,197
10 Day Avg. Volume70,026
30 Day Avg. Volume41,406
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.81
Price to Sales (P/S)0.00
P/FCF Ratio-3.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA lack of reported debt and a still-positive equity base materially lowers near-term default risk and preserves strategic optionality. For a loss-making biotech, this balance-sheet structure lengthens runway for R&D and clinical programs without immediate refinancing pressure, supporting program continuity over months.
Improving Cash Burn In 2025Marked reduction in cash burn between 2024 and 2025 signals progress in cost control or program prioritization. Sustained burn-rate improvement is a durable positive because it reduces near-term financing needs, extends runway for clinical milestones, and increases probability of reaching inflection points with fewer dilutive financings.
Focused CNS Gene-therapy PipelineA specialized pipeline targeting central nervous system disorders provides structural advantages: high barriers to entry, potential orphan designations, and meaningful clinical value per approved program. If clinical progress continues, the focused therapy platform can create durable IP-led value that persists beyond short-term revenue cycles.
Bears Say
Revenue Collapsed To Near ZeroRevenue falling to essentially zero eliminates any operational self-funding and prevents leveraging fixed-cost investments. Over a multi-month horizon this forces reliance on external funding or asset sales, increasing execution risk and making it harder to sustain R&D programs without dilutive or conditional financing.
Sustained Negative Gross ProfitNegative gross profit indicates the core activities are not covering direct costs, not just overhead. That structural unprofitability suggests program economics or cost structure issues that must be corrected before scaling. Over months, persistent negative gross margins constrain path to commercial viability and pressure cash needs.
Eroding Equity And Shrinking AssetsMaterial decline in equity and asset base reduces the firm's capital cushion and increases sensitivity to further losses. Even without debt, depleted equity heightens likelihood of dilutive raises or asset disposals to fund operations, constraining strategic choices and increasing governance and shareholder dilution risks over the medium term.
LARK FAQ
What was CombiGene AB’s price range in the past 12 months?
CombiGene AB lowest stock price was kr1.75 and its highest was kr2.87 in the past 12 months.
What is CombiGene AB’s market cap?
CombiGene AB’s market cap is kr45.15M.
When is CombiGene AB’s upcoming earnings report date?
CombiGene AB’s upcoming earnings report date is Aug 21, 2026 which is in 29 days.
How were CombiGene AB’s earnings last quarter?
CombiGene AB released its earnings results on Feb 13, 2026. The company reported kr0.01 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.01.
Is CombiGene AB overvalued?
According to Wall Street analysts CombiGene AB’s price is currently Overvalued.
Does CombiGene AB pay dividends?
CombiGene AB pays a Notavailable dividend of kr2 which represents an annual dividend yield of 89.69%. See more information on CombiGene AB dividends here
What is CombiGene AB’s EPS estimate?
CombiGene AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CombiGene AB have?
CombiGene AB has 19,801,197 shares outstanding.
What happened to CombiGene AB’s price movement after its last earnings report?
CombiGene AB reported an EPS of kr0.01 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.83%.
Which hedge fund is a major shareholder of CombiGene AB?
Currently, no hedge funds are holding shares in SE:LARK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CombiGene AB
Lärkberget AB (publ) functions as an investment firm, engaging in a variety of financial endeavors. Its operations encompass direct capital deployment into low-risk instruments, broader financial investments, acquiring stakes in privately held yet profitable companies, and serving as a vehicle for reverse acquisitions. Established in 1990 and based in Östermalm, Sweden, the company transitioned to its current name, Lärkberget AB (publ), in June 2025, having formerly operated as CombiGene AB (publ).